Dienogest

Brand names: Natazia · Active ingredient: Dienogest

In short: Natazia™ is indicated for use by women to prevent pregnancy. The efficacy of Natazia in women with a body mass index (BMI) of > 30 kg/m2 has not been evaluated.

Forms & strengthsNatazia (estradiol valerate and estradiol valerate/dienogest) tablets are available in blister packs. Each blister pack (28 film-coated tablets) contains in the following order: 2 dark yellow tablets each containing 3 mg estradiol valerate 5 medium red …
LabelPhysicians Total Care, Inc.
Label updatedApr 19, 2011

What is Dienogest used for?

Natazia™ is indicated for use by women to prevent pregnancy.

The efficacy of Natazia in women with a body mass index (BMI) of > 30

kg/m2 has not been evaluated.

⚠ Boxed warning (FDA's strongest warning)

Cigarette smoking increases the risk of serious

cardiovascular events from combination oral contraceptive (COC) use. This risk

increases with age, particularly in women over 35 years of age, and with the

number of cigarettes smoked. For this reason, COCs should not be used by women

who are over 35 years of age and smoke.

Dienogest dosage

Enter section text here

To achieve maximum contraceptive effectiveness, Natazia must be

taken exactly as directed. Take one tablet by mouth the same time every day.

Tablets must be taken in the order directed on the blister pack. Tablets should

not be skipped or intake delayed by more than 12 hours. For patient instructions

for missed pills, see FDA-Approved Patient Labeling.

Instruct the patient to begin taking Natazia on Day 1 of her

menstrual cycle (that is, the first day of her menstrual bleeding) . Instruct the patient

to use a non-hormonal contraceptive as back-up during the first 9 days.

For postpartum women who do not breastfeed or after a second trimester

abortion, Natazia may be started no earlier than 4 weeks postpartum. Recommend

use of a non-hormonal back-up method for the first 9 days. When combined oral

contraceptives (COCs) are used during the postpartum period, the increased risk

of thromboembolic disease associated with the postpartum period must be

considered. The possibility of ovulation and conception before starting COCs

should also be considered.

If the patient is switching from a combination hormonal method such as:

Another pill

Vaginal ring

Patch

Instruct her to take the first dark yellow pill on the first day of her

withdrawal bleed. She should not continue taking the pills from her previous

birth control pack. If she does not have a withdrawal bleed, rule out pregnancy

before starting Natazia.

If she previously used a vaginal ring or transdermal patch, she should start

using Natazia on the day the ring or patch is removed.

Instruct the patient to use a non-hormonal back-up method such as a condom

or spermicide for the first 9 days.

If the patient is switching from a progestin-only method such as a:

Progestin-only pill

Implant

Intrauterine system

Injection

Instruct her to take the first dark yellow pill on the day she would have

taken her next progestin-only pill or on the day of removal of her implant or

intrauterine system or on the day when she would have had her next injection.

Instruct the patient to use a non-hormonal back-up method such as a condom

or spermicide for the first 9 days.

In case of severe vomiting or diarrhea, absorption may not be

complete and additional contraceptive measures should be taken. If vomiting or

diarrhea occurs within 3-4 hours after taking a colored tablet, this can be

regarded as a missed tablet.

How to take Dienogest — instructions & advice from the label

See FDA-Approved Patient Labeling.

Counsel patients that cigarette smoking increases the risk of serious

cardiovascular events from COC use, and that women who are over 35 years old and

smoke should not use COCs.

Counsel patients that this product does not protect against HIV infection

(AIDS) and other sexually transmitted diseases.

Counsel patients on Warnings and Precautions associated with COCs.

Counsel patients to take one tablet daily by mouth at the same time every

day in the exact order noted on the blister. Instruct patients what to do in the

event pills are missed. See What Should I

Do if I Miss any Pills section or FDA-Approved Patient

Labeling.

Counsel women who are taking strong CYP3A4 inducers (for example,

carbamazepine, phenytoin, rifampicin, and St. John’s wort) not to choose Natazia

as their oral contraceptive due to the possibility of decreased contraceptive

efficacy.

Counsel patients to use a back-up or alternative method of contraception

when weak or moderate enzyme inducers are used with Natazia.

Counsel patients who are breastfeeding or who desire to breastfeed that COCs

may reduce breast milk production. …

Warnings & precautions

Do not take this medicine if: Do not prescribe Natazia to women who are known to have the

following:

A high risk of arterial or venous thrombotic diseases. Examples include

women who are known to:

Smoke, if over age 35

Have deep vein thrombosis or pulmonary embolism, now or in the past

Have cerebrovascular disease

Have coronary artery disease

Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for

example, subacute bacterial endocarditis with valvular disease, or atrial

fibrillation)

Have inherited or acquired hypercoagulopathies

Have uncontrolled hypertension

Have diabetes with vascular disease

Have headaches with focal neurological symptoms or have migraine headaches

with or without aura if over age 35

Undiagnosed abnormal genital bleeding

Breast cancer or other estrogen- or progestin-sensitive cancer, now or in

the past

Liver tumors, benign or malignant, or liver disease [see

Warnings and Precautions (

5.3

),

Use in Specific Populations (8.7) and

Clinical Pharmacology (12.3)].

Pregnancy, because there is no reason to use COCs during pregnancy .

Enter section text here

Stop COCs if an arterial or deep venous thrombotic (VTE) event

occurs. Although the use of COCs increases the risk of venous thromboembolism,

pregnancy increases the risk of venous thromboembolism as much or more than the

use of COCs. The risk of venous thromboembolism in women using COCs is 3 to 9

per 10,000 woman-years. The excess risk is highest during the first year of use

of a COC. Use of COCs also increases the risk of arterial thromboses such as

strokes and myocardial infarctions, especially in women with other risk factors

for these events. The risk of thromboembolic disease due to oral contraceptives

gradually disappears after COC use is discontinued. …

Dienogest side effects

The following serious adverse reactions with the use of COCs are

discussed elsewhere in the labeling:

Serious cardiovascular events and smoking

Vascular events

Liver disease

Adverse reactions commonly reported by COC users are:

Irregular uterine bleeding

Nausea

Breast tenderness

Headache

Because clinical trials are conducted under widely varying

conditions, adverse reaction rates observed in the clinical trials of a drug

cannot be directly compared to rates in the clinical trials of another drug and

may not reflect the rates observed in practice.

Two multicenter phase 3 clinical trials evaluated the safety and

efficacy of Natazia for pregnancy prevention. Both were non-comparative,

open-labeled, single-arm studies with a treatment duration up to 28 cycles. A

total of 1,867 women aged 18–50 were enrolled and took at least one dose of

Natazia.

Adverse Reactions Leading to Study Discontinuation:

11.5% of the women discontinued from the clinical trials due to an adverse

reaction; the most frequent adverse reactions leading to discontinuation were

metrorrhagia and irregular menstruation (1.9%), acne (1.2%), headache and

migraine (1.0%), and weight increase (0.7 %).

Common Treatment-Emergent Adverse Reactions (≥ 2%):

headache (including migraines) (13.2%), metrorrhagia and irregular menstruation

(8.0%), breast pain, discomfort or tenderness (6.6%), nausea or vomiting (6.5%),

acne (3.9%) and increased weight (2.8%). …

Drug interactions

Enter section text here

Interactions between oral contraceptives and other drugs may lead

to breakthrough bleeding and/or contraceptive failure. The following

interactions have been reported in the literature for COCs in general or were

studied in clinical trials with Natazia.

CYP3A4 Inducers: Drugs or

herbal products that induce certain enzymes, including CYP3A4, may decrease the

effectiveness of COCs or increase breakthrough bleeding. Some drugs or herbal

products that may decrease the effectiveness of hormonal contraceptives include

barbiturates, bosentan, felbamate, griseofulvin, oxcarbazepine, and topiramate.

Counsel women to use an alternative method of contraception or a back-up method

when moderate or weak enzyme inducers are used with COCs, and to continue

back-up contraception for 28 days after discontinuing the enzyme inducer to

ensure contraceptive reliability.

Dienogest is a substrate of cytochrome P450 (CYP) 3A4. Women who take

medications that are strong CYP3A4 inducers (for example, carbamazepine,

phenytoin, rifampicin, and St. John’s wort) should not choose Natazia as their

oral contraceptive while using these inducers and for at least 28 days after

discontinuation of these inducers due to the possibility of decreased

contraceptive efficacy. …

About this medicine

Natazia (estradiol valerate and estradiol valerate/dienogest)

tablets provide an oral contraceptive regimen consisting of 26 active

film-coated tablets that contain the active ingredients specified for each

tablet below, followed by two inert tablets:

2 dark yellow tablets each containing 3 mg estradiol valerate

5 medium red tablets each containing 2 mg estradiol valerate and 2 mg

dienogest

17 light yellow tablets each containing 2 mg estradiol valerate and 3 mg

dienogest

2 dark red tablets each containing 1 mg estradiol valerate

2 white tablets (inert)

Natazia also contains the excipients lactose monohydrate, maize starch, maize

starch pre-gelatinized, povidone 25, magnesium stearate, hypromellose, macrogol

6000, talc, titanium dioxide, and ferric oxide pigment, yellow, or ferric oxide

pigment, red.

The empirical formula of estradiol valerate is C23

H32 O3 and the chemical structure

is:

Estradiol Valerate

The chemical name of estradiol valerate is

Estra-1,3,5(10)-triene-3,17-diol(17ß)-,17-pentanoate. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 3fbcd7d8-cc53-4dbb-8edc-451acadc472c. Read the full official label on DailyMed.